NASDAQ:ATYR aTyr Pharma Q3 2025 Earnings Results & Report $0.20 -0.01 (-6.38%) Closing price 04:00 PM EasternExtended Trading$0.20 +0.00 (+0.94%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. aTyr Pharma missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.26 versus the -$0.20 consensus estimate, while revenue of $0.19 million fell short of the $0.91 million estimate by $0.72 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call4:00 PM ET aTyr Pharma EPS ResultsActual EPS-$0.26Consensus EPS -$0.20Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersaTyr Pharma Revenue ResultsActual Revenue$0.19 millionExpected Revenue$0.91 millionBeat/MissMissed by -$719.00 thousandYoY Revenue GrowthN/AUpcoming EarningsaTyr Pharma's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) aTyr Pharma Q3 2025 Earnings FAQ Did aTyr Pharma beat earnings estimates for Q3 2025? aTyr Pharma (NASDAQ:ATYR) reported earnings of -$0.26 per share for Q3 2025, missing the consensus estimate of -$0.20. The report was announced on Thursday, November 6, 2025. What was aTyr Pharma's revenue for Q3 2025? aTyr Pharma reported revenue of $0.19 million for Q3 2025, against a consensus estimate of $0.91 million. When is aTyr Pharma's next earnings date? aTyr Pharma's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for aTyr Pharma on the company's earnings history page. aTyr Pharma Earnings HeadlinesaTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological ChemistryOctober 13 at 8:00 AM | globenewswire.comaTyr Pharma (NASDAQ:ATYR) Shares Down 2.3% - Here's What HappenedOctober 7, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 13 at 1:00 AM | InvestorPlace (Ad)Positive FDA Alignment Boosts ATyr Pharma's Rare Lung DiseaseSeptember 24, 2026 | benzinga.comATyr Pharma, Inc. Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary SarcoidosisSeptember 24, 2026 | marketscreener.comMPerché il titolo aTyr Pharma è in rialzo oggi?September 24, 2026 | it.investing.comSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) (NASDAQ: ATYR) is a biotechnology company focused on developing medicines that regulate immune responses and treat serious diseases. The company’s research is based on the therapeutic potential of extracellular functions of tRNA synthetases, a group of proteins traditionally known for their role in protein production but increasingly studied for their involvement in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein based on histidyl-tRNA synthetase. It is designed to modulate immune activity through neuropilin-2 and has been developed primarily for pulmonary sarcoidosis, a rare inflammatory lung disease. The company has also investigated efzofitimod in other inflammatory and fibrotic conditions, while evaluating additional product candidates aimed at diseases involving immune-system dysfunction. Founded in 2005 and headquartered in San Diego, California, aTyr conducts its research and clinical development activities in collaboration with medical institutions, research organizations and industry partners. The company’s leadership includes Sanjay S. Shukla, M.D., who serves as president and chief executive officer. aTyr’s programs have received regulatory recognition, including orphan-drug and Breakthrough Therapy designations for efzofitimod in pulmonary sarcoidosis.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
